Yanhong Deng
Statistician 3Cards
About
Research
Publications
2026
Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study.
Xie X, Lin Z, Li W, Xie Y, Zhang J, Hu H, Li S, Zhai X, Shi L, Deng Y. Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study. Journal Of Clinical Oncology 2026, 44: 124-124. DOI: 10.1200/jco.2026.44.2_suppl.124.Peer-Reviewed Original ResearchWild-type metastatic colorectal cancerMetastatic colorectal cancerMaximum tolerated doseDose-limiting toxicityDose-escalation studyColorectal cancerSerum concentrationsFirst-line maintenance treatmentPharmacokinetic parametersSchedule of cetuximabConcentrations of cetuximabQ3w scheduleDose escalationInduction therapyMaintenance therapyPharmacokinetic exposureQ3wSafety profileCetuximabMaintenance treatmentAdverse eventsCapecitabinePharmacokinetic analysisPhase IbPharmacokinetic reference
2025
Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial
Zhang T, Shi L, Jian L, Jiang J, Qiu Y, Xie F, Zhang J, Peng H, Zhong L, Chen Y, Zhong Y, Deng Y. Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial. Annals Of Surgical Oncology 2025, 1-13. PMID: 41379261, DOI: 10.1245/s10434-025-18802-8.Peer-Reviewed Original ResearchLocally Advanced Rectal CancerLong-course chemoradiotherapyHigh-risk patientsQuality-adjusted life yearsAdvanced rectal cancerNeoadjuvant treatmentPatient-reported outcomesHealth outcomesProspective trialsRectal cancerNeoadjuvant treatment of locally advanced rectal cancerTreatment of locally advanced rectal cancerOutcomes of adverse eventsYear Follow-UpSocial life impactsFOLFOX groupSupplementary radiotherapyClinical benefitFOLFOXTreatment paradigmHealth utilityAdverse eventsFollow-upHealthcare resourcesCost-effectiveHepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation
Haque L, Choi H, Justen M, Deng Y, Edelman E, Fiellin D. Hepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation. Hepatology Communications 2025, 9: e0818. PMID: 41085538, PMCID: PMC12520222, DOI: 10.1097/hc9.0000000000000818.Peer-Reviewed Original ResearchConceptsHepatology clinicAUD treatmentAddiction treatmentMixed-methods formative evaluationTreatment of AUDUrban academic medical centerAcademic medical centerSemi-structured interviewsLiver diseaseHepatologyPractice patternsMedical CenterTobacco useClinicClinical toolOpioidImplementation science frameworkTreatmentPatientsFlexible care modelsAddictionCliniciansDisorder treatmentOUDMedicationNeoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial
Shen X, Cai Y, Li W, Shi L, Zhang J, Xie X, Wu Z, Zheng Z, Cao W, Deng Y, Hu H. Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial. EClinicalMedicine 2025, 88: 103499. PMID: 41181826, PMCID: PMC12572784, DOI: 10.1016/j.eclinm.2025.103499.Peer-Reviewed Original ResearchLow symptom burdenNeoadjuvant PD-1 blockadePD-1 blockadePathological complete responseSymptom burdenMismatch repair deficiencyColorectal cancerQLQ-C30 function scoreMicrosatellite instability-highNeoadjuvant toripalimabComplete responseRepair deficiencySurvival rateSecondary endpointsSingle-centreParallel-groupFollow-upRate of pathological complete responseQuality of lifeLocalized colorectal cancer patientsRandomised phase 2 trialNational Natural Science FoundationDisease-free survival ratesEvent-free survival rateLocally advanced colorectal cancerGlycolysis-Driven Immune Evasion in Microsatellite Instability-High Colorectal Cancer: An Integrated Single-Cell and Spatial Transcriptomics Study
Li C, Cai P, Zeng H, Li J, Hu H, Zhang J, Wu Z, Qin G, Deng Y. Glycolysis-Driven Immune Evasion in Microsatellite Instability-High Colorectal Cancer: An Integrated Single-Cell and Spatial Transcriptomics Study. OncoTargets And Therapy 2025, 18: 1027-1042. PMID: 40990035, PMCID: PMC12452990, DOI: 10.2147/ott.s538018.Peer-Reviewed Original ResearchMicrosatellite instability-high colorectal cancerImmune checkpoint blockade resistanceCheckpoint blockade resistanceImmune evasionColorectal cancerResistance to immune checkpoint blockadeImmune checkpoint blockadeT-cell depletionCopy number variation analysisTumor-associated macrophagesProportion of patientsColorectal cancer patientsCheckpoint blockadeNeoantigen loadImmunosuppressive nicheTreg accumulationImmunosuppressive phenotypeTreg differentiationPrognostic implicationsEpithelial subpopulationsGene Set Enrichment AnalysisImmune cellsPoor prognosisTumor subpopulationsCancer patients796P A phase II trial to evaluate the safety and efficacy of SSGJ-707: A bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic CRC
Xu X, Li W, Liu T, Zhang Y, Du X, Niu Z, Qiu H, Guo Z, Deng Y, Cai M, Lv J, Feng L, Zong H, Liu M, Xiang X, Zheng Y, Guo Y, Wu T, Lou J, Song W. 796P A phase II trial to evaluate the safety and efficacy of SSGJ-707: A bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic CRC. Annals Of Oncology 2025, 36: s542. DOI: 10.1016/j.annonc.2025.08.1369.Peer-Reviewed Original Research800P A multicenter randomised phase II trial assessing the efficacy and safety mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Updated results of the CAPCET study
Zhou Y, Chen P, Wang J, Jin Y, Li Y, Chen C, Qiu H, Shen Y, Liu H, Huang L, Xie L, Deng Y, Chen X, Yang L, Lei Z, Bai L, Cao P, Wei G, Zhang T, Qiu M. 800P A multicenter randomised phase II trial assessing the efficacy and safety mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Updated results of the CAPCET study. Annals Of Oncology 2025, 36: s544. DOI: 10.1016/j.annonc.2025.08.1373.Peer-Reviewed Original Research56eP Targeting the RMI2-RAD51 axis restores anti-PD-1 efficacy in MSS colorectal cancer by reprogramming immunosuppressive microenvironment via cGAS-STING activation
Zhan W, Cai R, Lyu X, Zhang J, Deng Y. 56eP Targeting the RMI2-RAD51 axis restores anti-PD-1 efficacy in MSS colorectal cancer by reprogramming immunosuppressive microenvironment via cGAS-STING activation. Annals Of Oncology 2025, 36: s225. DOI: 10.1016/j.annonc.2025.08.491.Peer-Reviewed Original ResearchFGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
Lyu X, Cai R, Han B, Liu Y, Zhang Y, Wu Z, Cheng Y, Lin Z, Qin G, Xie X, Zhang J, Zhan W, Deng Y. FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling. ESMO Open 2025, 10: 105561. PMID: 40834499, PMCID: PMC12529309, DOI: 10.1016/j.esmoop.2025.105561.Peer-Reviewed Original ResearchConceptsFibroblast growth factor receptorPrognostic impactImmunohistochemical scoring systemFGFR1 amplificationColorectal cancerFGFR alterationsNext-generation sequencingSurvival outcomesGenomic alterationsPredictors of poor disease-free survivalGenomic profilingFibroblast growth factor receptor alterationsPoor disease-free survivalSemiquantitative immunoreactive scoreProgression-free survivalDisease-free survivalMetastatic colorectal cancerInferior survival outcomesAggressive clinical behaviorCox regression analysisGrowth factor receptorRoutine pathology workflowImmunoreactive scoreUrothelial carcinomaKRAS/BRAF mutationsEfficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies
Yuan Y, Deng Y, Jin Y, Guo Z, Pan Y, Wang C, Wang Z, Hu Y, Hua D, Meng X, Zhang Z, Zhao M, Dong X, Huang D, Li X, Liu L, Sun M, Wang H, Wang X, Yang N, Zhang M, Hu S, Wu D, Huang J, Zhang S, Huang M, Ding K. Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies. Signal Transduction And Targeted Therapy 2025, 10: 241. PMID: 40715048, PMCID: PMC12297441, DOI: 10.1038/s41392-025-02315-7.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsDisease control rateObjective response rateProgression-free survivalMetastatic colorectal cancerPhase I partColorectal cancerChinese patientsOverall survivalMedian durationMedian duration of treatmentI partGrade 3 TRAEsNo grade 4Median Follow-UpDuration of treatmentAnti-tumor activityDose interruptionMedian OSTreatment discontinuationDose reductionPrimary endpointSecondary endpointsSolid tumorsClinical efficacy
Academic Achievements & Community Involvement
News
News
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- June 15, 2021
Pneumocystis Pneumonia Outbreak Chronicled In Clinical Infectious Diseases
Get In Touch
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511